Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
A Manual for Pick High Evaluated Food Conveyance Administrations In Significant Urban communities For 2024 - 2Factbox-Artemis II crew includes first woman, Black astronaut and Canadian ever flown to moon
- 3More parents refusing this shot that prevents serious bleeding at birth
- 4Involved Vehicles for Seniors: Track down the Best Picks for Solace and Dependability
- 5Vote In favor of Your Favored Pizza Cover
- Ukraine apologizes to Finland for crashed drones
- A Time of Careful Eating: Individual Tests in Nourishment
- Novartis eyes more bolt-on acquisitions, CEO says
- US bishops officially ban gender-affirming care at Catholic hospitals
- Linda Hamilton, 69, says she doesn't want to 'chase longevity'
- Intriguing Strange Cruising Objections you Should Visit
- Most loved Public Dish: Which One Addresses Its Nation Best?
- The Secret Side of Italy: 12 Underrated Destinations Locals Don’t Want Tourists to Find
- Instructions to Figure out the Various Phases of Cellular breakdown in the lungs
